VRC01LS

VRC01LS is a humanized monoclonal antibody inhibitor targeting the CD4-binding site of HIV-1 envelope glycoprotein (Env) . VRC01LS blocks the binding of HIV-1 to host cell CD4 receptor, inhibiting viral entry. VRC01LS is promising for research of HIV-1 infection[1][2].

Product Specifications

UNSPSC

12352203

Target

HIV; Virus Protease

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Purity

98.78

Smiles

[VRC01LS]

Molecular Weight

(145.94 kDa)

References & Citations

[1]Happe M, et al. Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection. JCI Insight. 2025 Feb 24;10 (4) :e181496.|[2]Gaudinski MR, et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Med. 2018 Jan 24;15 (1) :e1002493.